Published in PLoS One on January 12, 2012
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene (2013) 1.25
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther (2012) 1.03
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Genomic, prognostic, and cell-signaling advances in uveal melanoma. Am Soc Clin Oncol Educ Book (2013) 0.94
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther (2014) 0.91
A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife (2015) 0.87
GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy? Cancer Cell (2014) 0.86
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget (2016) 0.85
Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene (2014) 0.83
Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures. Chem Commun (Camb) (2014) 0.82
Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. PLoS One (2013) 0.81
Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells. Am J Physiol Renal Physiol (2013) 0.80
INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal (2014) 0.79
ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. Cancer Cell (2016) 0.77
Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation. Invest Ophthalmol Vis Sci (2014) 0.76
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem (2000) 5.84
Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle (2003) 4.55
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal (2005) 2.32
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A (2006) 2.10
Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol (2000) 2.07
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol (2007) 1.63
Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res (2001) 1.55
Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol (2004) 1.55
Protein kinase C (PKC) family in cancer progression. Cancer Lett (2006) 1.54
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood (2002) 1.45
Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res (2003) 1.38
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem (2003) 1.33
Classical PKC isoforms in cancer. Pharmacol Res (2007) 1.29
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol (2003) 1.29
Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist (2002) 1.29
Lack of BRAF mutations in uveal melanoma. Cancer Res (2003) 1.27
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood (2006) 1.23
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res (2008) 1.17
The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res (2004) 1.12
Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res (2008) 1.11
Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett (2003) 1.09
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther (2006) 1.09
Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci (2007) 1.08
Authenticating cell lines in ophthalmic research laboratories. Invest Ophthalmol Vis Sci (2008) 1.03
Targeted therapy for uveal melanoma. Cancer Treat Rev (2008) 1.03
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol (2010) 1.01
Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. J Biol Chem (2003) 1.01
Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer (2007) 0.97
Protein kinase Cbeta is an effective target for chemoprevention of colon cancer. Cancer Res (2009) 0.96
Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol (2006) 0.95
Metastatic uveal melanoma. Ophthalmol Clin North Am (2005) 0.95
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res (2007) 0.94
Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res (2009) 0.94
Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer (2008) 0.93
Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem (2008) 0.93
Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J (2001) 0.91
Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br J Cancer (2000) 0.88
The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett (2008) 0.88
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther (2008) 0.88
The past decade of experience with isolated hepatic perfusion. Oncologist (2004) 0.88
Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments. Invest New Drugs (2007) 0.87
Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells. Eur J Cancer (2009) 0.81
Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. Transl Oncol (2009) 0.80
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Open mesh versus laparoscopic mesh repair of inguinal hernia. N Engl J Med (2004) 8.24
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial. JAMA (2006) 6.34
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol (2002) 2.85
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med (2014) 2.80
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 2.51
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol (2011) 2.51
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Gastrointestinal stromal tumors. Virchows Arch (2010) 2.28
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol (2002) 2.19
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Does resident post graduate year influence the outcomes of inguinal hernia repair? Ann Surg (2005) 2.01
Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer (2007) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol (2012) 1.88
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res (2005) 1.87
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A (2012) 1.86
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol (2012) 1.83
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol (2004) 1.82
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A (2004) 1.81
Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res (2003) 1.81
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73
Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics (2007) 1.67
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64
USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res (2004) 1.64
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology (2013) 1.62
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46